Early “optimistic” data are available for the first two patients receiving Lineage Cell Therapeutics’ thaw-and-inject formulation of OpRegen via a new subretinal delivery system, according to a press release.
OpRegen is under study as a retinal epithelium transplant therapy in patients with advanced dry age-related macular degeneration with geographic atrophy.
The phase 1/2a study aims to evaluate the safety and efficacy of a single injection of human retinal pigment epithelium cells derived from an established pluripotent cell line in 24 patients divided into four cohorts.
Uncategorized